Evolution of cell & gene therapy in China: the case for universal CAR-T
China now represents 60% of clinical development in CAR-T therapy development globally: what have we learned to date and where are future opportunities?
Accelerating clinical development in China & the US
China and the US are the world’s largest oncology research destinations, and the clinical research bridge between them supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications.
Development and Regulatory Strategy for US and China
This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers. Additionally, it aims to understand the Evolving U.S. regulatory requirements for diversity in clinical cancer trials.
Go/No Go Decisions Based on Early Phase Oncology Trials
Understanding the latest regulatory and clinical developments in the field of Oncology in China, along with discussing the similarities and differences between Chinese oncology market and the overall global market, promote academic exchange and cooperation of the global oncology research and development ecosystem.
Driving efficiencies through virtual trial solutions in Asia Pacific
What is driving the acceleration of clinical trials in the Asia Pacific region and what are key considerations to maximise the opportunity for decentralised clinical trials in the future across the region.
Accelerating Clinical Trials in Rare Disease - Understanding Asia’s success as a rare disease clinical trial location
This webinar looks at Asia’s rare disease clinical trial landscape, why China is an increasingly attractive location for rare disease trials and critical program strategies to consider.
Expedited clinical development strategies for China
A two-part webinar interview and panel discussion with exclusive insights into China’s regulatory environment, the advantages of involving China sites, and strategies to accelerate entry in China.
아시아 태평양: 임상 시험 프로그램 가속화를 위한 솔루션
OCT Southeast의 Katrina Norial 발표 발표에서 Katrina Norial은 코로나 19 상황에서 임상 시험 연속성을 보장하고 개발 가속화를 위해 지역적 이점을 활용하는 Novotech의 역량을 논의합니다.
중국에서 임상 시험 시행시의 이점
중국은 생명공학 기업들이 임상 개발을 가속화할 수 있게 하는 중요한 기회를 제공하고 있습니다. 이번 세션에서는 다음 주제를 논의할 예정입니다:
• 중국 생명공학 임상시험의 최신 연구 및 동향
• 중국과 미국 규제 요건의 차이와 생명공학 기업들이 중국 기관을 포함시킴으로써 얻는 이점
• 스폰서와 시험자의 피드백
규제 마일스톤 및 사업 목표 달성
업계 전문가들로부터 간소화되고 핵심적인 글로벌 프로그램 전략의 중요성에 대한 설명을 듣고 제품 개발 계획 및 규제 문제에 대한 특별한 통찰력을 얻을 수 있습니다.
Managing Global Studies with Regional Partners
In this webinar, you'll learn about 1) Working with specialist CRO partners to maintain speed, flexibility, “fit” and regional expertise, 2) Leveraging technology and gold standard systems to provide integrated global management structure and reporting and 3) Advantages and tradeoffs of different global clinical trial setups.
Accelerating Clinical Trials in Australia and Asia – Presented by Steven Roan at OCT USA
Steven Roan breaks down the acceleration of clinical trials in Australia and Asia. The presentation is broken into three main segments. An introduction to Novotech and how Asia-Pacific is handling the COVID-19 pandemic, what Novotech is doing to support companies in these times, and finally talking about the benefits of working in Asia-Pacific for clinical trials.